Latest News for: rp1

Edit

BCA Retains Top Honor at the Annual Report Award, Followed by BCA Syariah in the Rp1 Trillion Cluster (PT Bank Central Asia Tbk)

Public Technologies 12 Dec 2025
BCA's achievement was also followed by PT Bank BCA Syariah, which was named the Grand Campion in the Rp1 Trillion cluster at the 2024 ARA ... BCA Grand Champion Rp1 Trillion Cluster ... Rp1 trillion cluster.
Edit

Prabowo to give Rp1 billion incentives for SEA Games gold medalists

Antara News 05 Dec 2025
Jakarta (ANTARA) - President Prabowo Subianto promised an incentive of Rp1 billion (approximately US$58,000) to Indonesian athletes who win gold medals at the 33rd SEA Games in Thailand.
Edit

Ministry raises Rp1.5 bln for flood-hit cultural heritage in Sumatra

Antara News 04 Dec 2025
Jakarta (ANTARA) - The Indonesian Ministry of Culture has raised Rp1.5 billion (around US$90,000) to help manage the impact of floods and landslides on cultural heritage sites in Aceh, North Sumatra, and West Sumatra ... Related news ... Related news ... Editor.
Edit

Unwavering Contribution: PT TIMAH Tbk Pays Rp1 Trillion (PT Timah Tbk)

Public Technologies 19 Nov 2025
PT TIMAH Tbk Pays Rp1 Trillion in Taxes and Non-Tax Revenue to Support National Development ... state contributions through tax payments and Non-Tax State Revenue (PNBP) amounting to Rp1.053 trillion.
Edit

Govt probes Rp1 billion loss in West Bandung free meals program

Antara News 07 Nov 2025
Jakarta (ANTARA) - Indonesia's National Nutrition Agency (BGN) has reported the loss of Rp1 billion in operational funds from a Free Meals (MBG) program kitchen in West Bandung District, West Java, to the Indonesian National Police (Polri).
Edit

RP1 + Nivolumab in Patients with and without prior BRAF-Directed Therapy at SITC 2025 (Replimune Group Inc)

Public Technologies 07 Nov 2025
611 RP1 plus nivolumab in patients with and without prior BRAF-directed therapy ... To assess the impact of BRAF mutation status and prior BRAFi/MEKi therapy on the efficacy of RP1 plus nivolumab from a post hoc subgroup analysis of the IGNYTE trial.
Edit

RP1 + Nivolumab in Patients with Advanced Anti–PD-1–Failed Melanoma at SITC 2025 (Replimune Group Inc)

Public Technologies 07 Nov 2025
600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma ... RP1* ... RP1** + Nivo† ... RP1 ... RP1 readministration could occur as monotherapy if nivo was stopped due to nivo-related toxicity ... additional RP1 doses.
Edit

Maybank Indonesia 9M FY25 PBT rises 53.9% to Rp1.30 trillion 31 October 2025 (PT Bank Maybank Indonesia Tbk)

Public Technologies 31 Oct 2025
Maybank Indonesia 9M FY25 PBT rises 53.9% to Rp1.30 trillion. 9M FY25 Preview (Y-o-Y) PBT up 53.9% to Rp1.30 trillion while PATAMI rose 77.3% to Rp989 billion Gross Operating Income rose 2.9% to Rp6.95 trillion, backed by.
Edit

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Nasdaq Globe Newswire 20 Oct 2025
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026. Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 ... .
Edit

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma (Form 8-K) (Replimune Group Inc)

Public Technologies 20 Oct 2025
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma ... "We are pleased the agency has accepted the resubmission of our BLA for RP1," said Sushil Patel, Ph.D., CEO of Replimune ... About RP1.
Edit

Indonesia recovers Rp1.7T in corruption funds in Prabowo's first year

Antara News 19 Oct 2025
Jakarta (ANTARA) - Indonesia has successfully recovered Rp1.7 trillion (US$102.5 million) in embezzled state funds from corruption suspects during the first year of President Prabowo Subianto’s administration ... Related news ... Related news ... Editor.
Edit

RP1 + Nivolumab in Patients with NMSC at ESMO 2025 (Replimune Group Inc)

Public Technologies 18 Oct 2025
Efficacy and safety of RP1 + nivolumab (nivo) in patients with non-melanoma skin cancer (NMSC) ... To report the efficacy and safety of RP1 plus nivolumab in the NMSC cohort from the IGNYTE trial ... RP1 1 × 106 ... RP1 + weeks.
×